{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Akt", "glutathione", "isoalantolactone", "ovarian cancer", "reactive oxygen species"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36727416", "DateCompleted": {"Year": "2023", "Month": "04", "Day": "05"}, "DateRevised": {"Year": "2023", "Month": "05", "Day": "06"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.3724/abbs.2023003"], "Journal": {"ISSN": "1745-7270", "JournalIssue": {"Volume": "55", "Issue": "1", "PubDate": {"Year": "2023", "Month": "Feb", "Day": "25"}}, "Title": "Acta biochimica et biophysica Sinica", "ISOAbbreviation": "Acta Biochim Biophys Sin (Shanghai)"}, "ArticleTitle": "Dual regulation of Akt and glutathione caused by isoalantolactone effectively triggers human ovarian cancer cell apoptosis.", "Pagination": {"StartPage": "62", "EndPage": "71", "MedlinePgn": "62-71"}, "Abstract": {"AbstractText": ["Ovarian cancer is one of leading causes of cancer death in gynecological tumor. Isoalantolactone (IL), present in several medicinal plants, exhibits various biological activities, and its mechanism underlying anti-ovarian cancer activity needs to be further investigated. Here, we find that IL inhibits the proliferation of SKOV-3 and OVCAR-3 cells by causing G2/M phase arrest and inducing apoptosis. Moreover, IL decreases intracellular glutathione (GSH) level, and induces reactive oxygen species (ROS) generation in SKOV-3 cells. Furthermore, IL induces inactivation of Akt which is required for the cytotoxicity of IL. In addition, overexpression of Akt attenuates the IL-induced growth inhibition and ROS generation. GSH supplementation moderately increases the expression of phospho-Akt. Further investigation reveals that pretreatment with L-buthionine-sulfoximine (a GSH biosynthesis inhibitor) restores the Akt-mediated attenuation of growth inhibition induced by IL. Moreover, co-treatment with IL and wortmannin (an Akt pathway inhibitor) increases the growth inhibition attenuated by pretreatment with N-acetyl-L-cysteine (a precursor for GSH biosynthesis). These results indicate that inactivation of Akt and downregulation of GSH level induced by IL are related to each other. In conclusion, combined targeting Akt and GSH is an effective strategy for cancer therapy and IL can be a promising anticancer agent for further exploration."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, China."}, {"Identifier": [], "Affiliation": "Baiyunshan Pharmaceutical General Factory, Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., Guangzhou 510515, China."}], "LastName": "Xie", "ForeName": "Zhoufan", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, China."}], "LastName": "Xu", "ForeName": "Jie", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, China."}], "LastName": "Xiao", "ForeName": "Di", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Renmin Hospital, Wuhan University, Wuhan 430060, China."}], "LastName": "Lei", "ForeName": "Jiachuan", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, China."}, {"Identifier": [], "Affiliation": "Department of Pharmacy, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China."}], "LastName": "Yu", "ForeName": "Jianqing", "Initials": "J"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "China", "MedlineTA": "Acta Biochim Biophys Sin (Shanghai)", "NlmUniqueID": "101206716", "ISSNLinking": "1672-9145"}, "ChemicalList": [{"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "Proto-Oncogene Proteins c-akt"}, {"RegistryNumber": "0", "NameOfSubstance": "Reactive Oxygen Species"}, {"RegistryNumber": "BYH07P620U", "NameOfSubstance": "isoalantolactone"}, {"RegistryNumber": "GAN16C9B8O", "NameOfSubstance": "Glutathione"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Apoptosis"}, {"QualifierName": ["metabolism"], "DescriptorName": "Proto-Oncogene Proteins c-akt"}, {"QualifierName": ["metabolism"], "DescriptorName": "Reactive Oxygen Species"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Ovarian Neoplasms"}, {"QualifierName": ["metabolism"], "DescriptorName": "Glutathione"}, {"QualifierName": [], "DescriptorName": "Cell Proliferation"}], "CoiStatement": "The authors declare no potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, Linder T, Wawrosch C, Uhrin P, Temml V, et al.  Discovery and resupply of pharmacologically active plant-derived natural products: a review. \nBiotechnol Adv. \n. 2015;33:1582\u20131614. doi: 10.1016/j.biotechadv.2015.08.001.", "ArticleIdList": ["10.1016/j.biotechadv.2015.08.001", "PMC4748402", "26281720"]}, {"Citation": "Schmidt TJ, Brun R, Willuhn G, Khalid SA. Anti-trypanosomal activity of helenalin and some structurally related sesquiterpene lactones. \nPlanta med. \n. 2002;68:750\u2013751. doi: 10.1055/s-2002-33799.", "ArticleIdList": ["10.1055/s-2002-33799", "12221603"]}, {"Citation": "Stojanovi\u0107-Radi\u0107 Z, \u010comi\u0107 L, Radulovi\u0107 N, Blagojevi\u0107 P, Deni\u0107 M, Miltojevi\u0107 A, Rajkovi\u0107 J, et al.  Antistaphylococcal activity of\nInula helenium L. root essential oil: eudesmane sesquiterpene lactones induce cell membrane damage\n. \nEur J Clin Microbiol Infect Dis. \n. 2012;31:1015\u20131025. doi: 10.1007/s10096-011-1400-1.", "ArticleIdList": ["10.1007/s10096-011-1400-1", "21901633"]}, {"Citation": "He G, Zhang X, Chen Y, Chen J, Li L, Xie Y. Isoalantolactone inhibits LPS-induced inflammation via NF-\u03baB inactivation in peritoneal macrophages and improves survival in sepsis. \nBiomed Pharmacother. \n. 2017;90:598\u2013607. doi: 10.1016/j.biopha.2017.03.095.", "ArticleIdList": ["10.1016/j.biopha.2017.03.095", "28407580"]}, {"Citation": "Khan M, Ding C, Rasul A, Yi F, Li T, Gao H, Gao R, et al.  Isoalantolactone induces reactive oxygen species mediated apoptosis in pancreatic carcinoma PANC-1 cells. \nInt J Biol Sci. \n. 2012;8:533\u2013547. doi: 10.7150/ijbs.3753.", "ArticleIdList": ["10.7150/ijbs.3753", "PMC3334669", "22532787"]}, {"Citation": "Rasul A, Di J, Millimouno F, Malhi M, Tsuji I, Ali M, Li J, et al.  Reactive oxygen species mediate isoalantolactone-induced apoptosis in human prostate cancer cells. \nMolecules. \n. 2013;18:9382\u20139396. doi: 10.3390/molecules18089382.", "ArticleIdList": ["10.3390/molecules18089382", "PMC6270412", "23921797"]}, {"Citation": "Jin C, Zhang G, Zhang Y, Hua P, Song G, Sun M, Li X, et al.  Isoalantolactone induces intrinsic apoptosis through p53 signaling pathway in human lung squamous carcinoma cells. \nPLoS ONE. \n. 2017;12:e0181731. doi: 10.1371/journal.pone.0181731.", "ArticleIdList": ["10.1371/journal.pone.0181731", "PMC5544200", "28777796"]}, {"Citation": "Xu R, Zhou G, Peng Y, Wang M, Li X. Pharmacokinetics, tissue distribution and excretion of isoalantolactone and alantolactone in rats after oral administration of Radix Inulae extract. \nMolecules. \n. 2015;20:7719\u20137736. doi: 10.3390/molecules20057719.", "ArticleIdList": ["10.3390/molecules20057719", "PMC6272429", "25927901"]}, {"Citation": "Yao D, Wang Y, Huo C, Wu Y, Zhang M, Li L, Shi Q, et al.  Study on the metabolites of isoalantolactone in vivo and in vitro by ultra performance liquid chromatography combined with Triple TOF mass spectrometry. \nFood Chem. \n. 2017;214:328\u2013338. doi: 10.1016/j.foodchem.2016.07.100.", "ArticleIdList": ["10.1016/j.foodchem.2016.07.100", "27507482"]}, {"Citation": "Zhou B, Ye J, Yang N, Chen L, Zhuo Z, Mao L, Liu Q, et al.  Metabolism and pharmacokinetics of alantolactone and isoalantolactone in rats: thiol conjugation as a potential metabolic pathway. \nJ Chromatography B. \n. 2018;1072:370\u2013378. doi: 10.1016/j.jchromb.2017.11.039.", "ArticleIdList": ["10.1016/j.jchromb.2017.11.039", "29223921"]}, {"Citation": "Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. \nCA Cancer J Clin. \n. 2021;71:7\u201333. doi: 10.3322/caac.21654.", "ArticleIdList": ["10.3322/caac.21654", "33433946"]}, {"Citation": "Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. \nCA Cancer J Clin. \n. 2011;61:183\u2013203. doi: 10.3322/caac.20113.", "ArticleIdList": ["10.3322/caac.20113", "PMC3576854", "21521830"]}, {"Citation": "Traverso N, Ricciarelli R, Nitti M, Marengo B, Furfaro AL, Pronzato MA, Marinari UM, et al.  Role of glutathione in cancer progression and chemoresistance. \nOxid Med Cell Longev. \n. 2013;2013:1\u201310. doi: 10.1155/2013/972913.", "ArticleIdList": ["10.1155/2013/972913", "PMC3673338", "23766865"]}, {"Citation": "Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP\u2013dependent transporters. \nNat Rev Cancer. \n. 2002;2:48\u201358. doi: 10.1038/nrc706.", "ArticleIdList": ["10.1038/nrc706", "11902585"]}, {"Citation": "Franco R, Cidlowski JA. Apoptosis and glutathione: beyond an antioxidant. \nCell Death Differ. \n. 2009;16:1303\u20131314. doi: 10.1038/cdd.2009.107.", "ArticleIdList": ["10.1038/cdd.2009.107", "19662025"]}, {"Citation": "Lee ER, Kim JY, Kang YJ, Ahn JY, Kim JH, Kim BW, Choi HY, et al.  Interplay between PI3K/Akt and MAPK signaling pathways in DNA-damaging drug-induced apoptosis. \nBiochim Biophys Acta. \n. 2006;1763:958\u2013968. doi: 10.1016/j.bbamcr.2006.06.006.", "ArticleIdList": ["10.1016/j.bbamcr.2006.06.006", "16905201"]}, {"Citation": "Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. \nNat Rev Drug Discov. \n. 2005;4:988\u20131004. doi: 10.1038/nrd1902.", "ArticleIdList": ["10.1038/nrd1902", "16341064"]}, {"Citation": "Rehfeldt SCH, Laufer S, Goettert MI. A highly selective\nin vitro JNK3 inhibitor, FMU200, restores mitochondrial membrane potential and reduces oxidative stress and apoptosis in SH-SY5Y cells\n. \nInt J Mol Sci. \n. 2021;22:3701. doi: 10.3390/ijms22073701.", "ArticleIdList": ["10.3390/ijms22073701", "PMC8037381", "33918172"]}, {"Citation": "Perumalsamy H, Sankarapandian K, Kandaswamy N, Balusamy SR, Periyathambi D, Raveendiran N. Cellular effect of styrene substituted biscoumarin caused cellular apoptosis and cell cycle arrest in human breast cancer cells. \nInt J Biochem Cell Biol. \n. 2017;92:104\u2013114. doi: 10.1016/j.biocel.2017.09.019.", "ArticleIdList": ["10.1016/j.biocel.2017.09.019", "28958615"]}, {"Citation": "Lei JC, Yu JQ, Yin Y, Liu YW, Zou GL. Alantolactone induces activation of apoptosis in human hepatoma cells. \nFood Chem Toxicol. \n. 2012;50:3313\u20133319. doi: 10.1016/j.fct.2012.06.014.", "ArticleIdList": ["10.1016/j.fct.2012.06.014", "22721982"]}, {"Citation": "Banerjee K, Basu S, Das S, Sinha A, Biswas MK, Choudhuri SK. Induction of intrinsic and extrinsic apoptosis through oxidative stress in drug-resistant cancer by a newly synthesized Schiff base copper chelate. \nFree Radical Res. \n. 2016;50:426\u2013446. doi: 10.3109/10715762.2015.1136062.", "ArticleIdList": ["10.3109/10715762.2015.1136062", "26733073"]}, {"Citation": "Xie Z, Guo Z, Wang Y, Lei J, Yu J. Protocatechuic acid inhibits the growth of ovarian cancer cells by inducing apoptosis and autophagy. \nPhytoTher Res. \n. 2018;32:2256\u20132263. doi: 10.1002/ptr.6163.", "ArticleIdList": ["10.1002/ptr.6163", "30047559"]}, {"Citation": "Zhou Y, Li Y, Shen J, Li J, Li X. Abemaciclib induces apoptosis in cardiomyocytes by activating the Hippo signaling pathway. \nActa Biochim Biophys Sin. \n. 2020;52:875\u2013882. doi: 10.1093/abbs/gmaa066.", "ArticleIdList": ["10.1093/abbs/gmaa066", "32556311"]}, {"Citation": "Mbaveng AT, Chi GF, Bonsou IN, Abdelfatah S, Tamfu AN, Yeboah EM, Kuete V, et al.  N-acetylglycoside of oleanolic acid (aridanin) displays promising cytotoxicity towards human and animal cancer cells, inducing apoptotic, ferroptotic and necroptotic cell death. \nPhytomedicine. \n. 2020;76:153261. doi: 10.1016/j.phymed.2020.153261.", "ArticleIdList": ["10.1016/j.phymed.2020.153261", "32559584"]}, {"Citation": "Hafeez BB, Siddiqui IA, Asim M, Malik A, Afaq F, Adhami VM, Saleem M, et al.  A dietary anthocyanidin delphinidin induces apoptosis of human prostate cancer PC3 Cells\nin vitro and\nin vivo: involvement of nuclear factor-\u03baB signaling\n. \nCancer Res. \n. 2008;68:8564\u20138572. doi: 10.1158/0008-5472.CAN-08-2232.", "ArticleIdList": ["10.1158/0008-5472.CAN-08-2232", "PMC3149885", "18922932"]}, {"Citation": "Franco R, Panayiotidis MI, Cidlowski JA. Glutathione depletion is necessary for apoptosis in lymphoid cells independent of reactive oxygen species formation. \nJ Biol Chem. \n. 2007;282:30452\u201330465. doi: 10.1074/jbc.M703091200.", "ArticleIdList": ["10.1074/jbc.M703091200", "PMC2267748", "17724027"]}, {"Citation": "Chio IIC, Jafarnejad SM, Ponz-Sarvise M, Park Y, Rivera K, Palm W, Wilson J, et al.  NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer. \nCell. \n. 2016;166:963\u2013976. doi: 10.1016/j.cell.2016.06.056.", "ArticleIdList": ["10.1016/j.cell.2016.06.056", "PMC5234705", "27477511"]}, {"Citation": "Lin CC, Lee CW, Chu TH, Cheng CY, Luo SF, Hsiao LD, Yang CM. Transactivation of Src, PDGF receptor, and Akt is involved in IL-1\u03b2-induced ICAM-1 expression in A549 cells. \nJ Cell Physiol. \n. 2007;211:771\u2013780. doi: 10.1002/jcp.20987.", "ArticleIdList": ["10.1002/jcp.20987", "17299794"]}, {"Citation": "Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, et al.  Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. \nLeukemia. \n. 2003;17:590\u2013603. doi: 10.1038/sj.leu.2402824.", "ArticleIdList": ["10.1038/sj.leu.2402824", "12646949"]}, {"Citation": "Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. \nCell Signal. \n. 2002;14:381\u2013395. doi: 10.1016/s0898-6568(01)00271-6.", "ArticleIdList": ["10.1016/s0898-6568(01)00271-6", "11882383"]}, {"Citation": "Maddika S, Ande S, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, et al.  Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. \nDrug Resistance Updates. \n. 2007;10:13\u201329. doi: 10.1016/j.drup.2007.01.003.", "ArticleIdList": ["10.1016/j.drup.2007.01.003", "17303468"]}, {"Citation": "Lien EC, Lyssiotis CA, Juvekar A, Hu H, Asara JM, Cantley LC, Toker A. Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer. \nNat Cell Biol. \n. 2016;18:572\u2013578. doi: 10.1038/ncb3341.", "ArticleIdList": ["10.1038/ncb3341", "PMC4848114", "27088857"]}, {"Citation": "Lin YH, Chen BYH, Lai WT, Wu SF, Guh JH, Cheng AL, Hsu LC. The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells. \nNaunyn Schmiedebergs Arch Pharmacol. \n. 2015;388:19\u201331. doi: 10.1007/s00210-014-1032-y.", "ArticleIdList": ["10.1007/s00210-014-1032-y", "25164962"]}, {"Citation": "Reddy NM, Kleeberger SR, Bream JH, Fallon PG, Kensler TW, Yamamoto M, Reddy SP. Genetic disruption of the Nrf2 compromises cell-cycle progression by impairing GSH-induced redox signaling. \nOncogene. \n. 2008;27:5821\u20135832. doi: 10.1038/onc.2008.188.", "ArticleIdList": ["10.1038/onc.2008.188", "PMC2646365", "18542053"]}, {"Citation": "Pundir M, Sharma A, Kumar J. Phytochemicals used as inhibitors in the treatment of ovarian cancer: a mini-review. \nMater Today-Proc. \n. 2022;48:1620\u20131625. doi: 10.1016/j.matpr.2021.09.505.", "ArticleIdList": ["10.1016/j.matpr.2021.09.505"]}, {"Citation": "Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, Massard C, et al.  Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. \nLancet. \n. 2021;398:131\u2013142. doi: 10.1016/S0140-6736(21)00580-8.", "ArticleIdList": ["10.1016/S0140-6736(21)00580-8", "34246347"]}, {"Citation": "Turner N, Howell S, Jhaveri K, Gomez H, Toi M, Hu X, Loibl S, et al.  350TiP A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+/HER2\u2013 breast cancer (CAPItello-291) \nAnn Oncol. \n. 2020;31:S388\u2013S389. doi: 10.1016/j.annonc.2020.08.452.", "ArticleIdList": ["10.1016/j.annonc.2020.08.452"]}, {"Citation": "Blagden SP, Hamilton AL, Mileshkin L, Wong S, Michael A, Hall M, Goh JC, et al.  Phase Ib dose escalation and expansion study of Akt inhibitor Afuresertib with carboplatin and paclitaxel in recurrent platinum-resistant ovarian cancer. \nClin Cancer Res. \n. 2019;25:1472\u20131478. doi: 10.1158/1078-0432.CCR-18-2277.", "ArticleIdList": ["10.1158/1078-0432.CCR-18-2277", "30563934"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "4", "Day": "5", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "2", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "2", "Day": "2", "Hour": "4", "Minute": "13"}, {"Year": "2023", "Month": "2", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["36727416", "PMC10157634", "10.3724/abbs.2023003"]}}], "PubmedBookArticle": []}